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Fourteen tri-deca polybrominated diphenyl ethers (PBDEs) were investigated in 35 human 25 
milk samples from Birmingham, UK. While none of the hepta-nona BDEs (the main 26 
components of the OctaBDE technical mixture) were above the limit of quantitation (LOQ); 27 
BDE-47 (average concentration = 3.3 ng g-1 lipid weight (lw)) was quantified in all samples 28 
contributing 34-74% to Σtri-hexa BDEs (the principal constituents of the PentaBDE 29 
commercial formulation). BDE-209 (the main congener in the DecaBDE formulation) was 30 
present above the LOQ in 69% of samples (average concentration = 0.31 ng g-1 lw). 31 
Concentrations of Σtri-hexa BDEs ranged from 0.2-26 ng g-1 lw with concentrations of BDE-32 
47 > BDE-153> BDE-99. While concentrations of Σtri-hexa BDEs in this study (average = 33 
5.95 ng g-1 lw) were at the high end of those reported from other European countries, 34 
concentrations of BDE-209 were lower than those reported in human milk from other 35 
countries. The average exposure of a UK nursing infant to Σtri-hexa BDEs (35 ng (kg bw)-1  36 
day-1) via breast milk exceeded the upper-bound dietary intakes of both UK adults and 37 
toddlers. Using a simple one compartment pharmacokinetic model, PBDE intakes of UK 38 
adults via inhalation, diet and dust ingestion were converted to predicted body burdens. 39 
Predictions compared well with those observed for Σtri-hexa BDEs and BDE-209 in breast 40 
milk.  41 









Polybrominated diphenyl ethers (PBDEs) have been extensively used as flame retardants for 51 
a wide range of consumer products including furniture, carpets, mattresses and casings for 52 
electronic equipment (BSEF 2013). Three technical PBDE formulations were commercially 53 
available: Penta (consisting primarily of BDE-47 and BDE-99 – 38-49% each, alongside 54 
smaller amounts of other tri- to hepta-BDEs), Octa (a mixture of hexa- to deca-BDEs – the 55 
exact congener composition varying substantially between the two principal formulations 56 
marketed) and Deca (92-97% decabromodiphenyl ether – BDE 209 – plus nona- (principally) 57 
and octa-BDEs) (La Guardia, et al. 2006). DecaBDE has dominated worldwide production 58 
with a global market demand of 56,100 tons in 2001, compared to 7,500 and 3,790 tons for 59 
PentaBDE and OctaBDE formulations respectively (BSEF 2013). Despite their utility, the 60 
persistence and bioaccumulative characters of these compounds have resulted in increasing 61 
concern over their potential adverse effects to human health (Frederiksen, et al. 2009; Harrad, 62 
et al. 2010). Animal studies have shown PBDEs to pose potential health risks including: 63 
endocrine disruption, neurodevelopmental and behavioural outcomes, hepatic abnormality 64 
and possibly cancer (Birnbaum and Staskal 2004; Darnerud 2008; Hakk 2010; Wikoff and 65 
Birnbaum 2011). The few data available from human epidemiological studies imply effects 66 
on: male reproductive hormones (Johnson, et al. 2013; Palace, et al. 2010), semen quality 67 
(Akutsu, et al. 2008), thyroid hormone homeostasis (Turyk, et al. 2008), cryptorchidism 68 
(Crump, et al. 2010), behavioral factors in pregnant women (Buttke, et al. 2013), as well as 69 
lower birth weight and length (Chao, et al. 2007; Lignell, et al. 2013). Such evidence has 70 
contributed to complete EU bans for Penta and OctaBDE, and restrictions on the use of 71 
DecaBDE in addition to other restrictions within several jurisdictions on the manufacture and 72 
new use of the three commercial PBDE formulations across the world (Harrad, et al. 2010). 73 
Moreover, PBDEs associated with Penta and OctaBDE have been listed under the UNEP 74 
Stockholm Convention on POPs, while DecaBDE is currently under consideration for listing 75 
under Annexes A, B and/or C to the convention (Stockholm convention on POPs 2009). 76 
Despite such restrictions, human exposure to PBDEs is likely to continue for the foreseeable 77 
future, given their persistence and ubiquity of flame-retarded consumer materials (Harrad and 78 
Diamond 2006). 79 
Several studies have reported different levels of PBDEs in various human tissues including 80 
serum, placenta, liver, adipose tissue and breast milk from different European, Asian and 81 
North American countries in the last few years (Cui, et al. 2012; Frederiksen, et al. 2009). 82 
These biomonitoring data provide a direct measurement of the human body burden of BFRs 83 
resulting from various external exposure pathways (e.g. inhalation, ingestion of dust, diet and 84 
water) and contribute to the risk assessment of such compounds. However, the only available 85 
information on BFRs in UK human samples is for tri- to hexa-BDEs (major components of 86 
the PentaBDE commercial product) where the median concentrations for Σtri-to hexa-BDEs 87 
in human milk and serum samples collected in 2003 were 6.3 and 4.18 ng g-1 lipid weight 88 
(lw) respectively (Kalantzi, et al. 2004). In addition, BDE-209 was detected in 11 out of 153 89 
serum samples at concentrations from 0.015-0.240 ng g-1 lw) (Thomas, et al. 2006). 90 
Current understanding is that non-occupational human exposure to PBDEs occurs mainly via 91 
a combination of diet, air and indoor dust (either via ingestion or dermal contact) 92 
(Frederiksen, et al. 2009; Lorber 2008; Trudel, et al. 2011). However, the extent to which the 93 
known contamination of indoor environments with PBDEs influences human body burdens 94 
remains unclear. While some studies have managed to establish significant positive 95 
correlations between the levels of PBDEs in food or indoor dust and their concentrations in 96 
human milk or serum (Dunn, et al. 2010; Thomsen, et al. 2008; Wu, et al. 2007); such 97 
correlations could not be established in other studies (Roosens, et al. 2009; Wang, et al. 98 
2013). An alternative approach involved application of a simple pharmacokinetic model to 99 
predict the body burdens of PBDEs in American adults using intake data from different 100 
exposure pathways. The predicted body burdens were then compared to the reported levels of 101 
PBDEs in human matrices and the relationship between external and internal exposure of 102 
American adults to PBDEs was discussed (Lorber 2008). 103 
To address this paucity of UK human biomonitoring data for PBDEs, this study reports 104 
concentrations of Σtri-hexa BDEs and for the first time BDE-209 in 35 human milk samples 105 
from Birmingham, UK. These data are then used to estimate the dietary exposure of UK 106 
nursing infants under different exposure scenarios. Finally, a simple, one-compartment 107 
pharmacokinetic model is applied to predict the body burdens of the studied PBDEs in UK 108 
adults (using indoor air and dust levels reported elsewhere by our research group for 109 
Birmingham, UK (Abdallah and Harrad 2010; Harrad and Abdallah 2011; Harrad, et al. 110 
2006; Harrad, et al. 2008a). The model predictions are then compared to the concentrations of 111 
target compounds measured in the analyzed human milk samples (used as indicator of adult 112 
female body burdens) for further understanding of the relationship between external and 113 
internal human exposure to PBDEs in UK adults.  114 
Materials and Methods 115 
Sample collection 116 
Breast milk samples (each comprising ~50 mL) were obtained from 35 adult healthy 117 
primiparous volunteers via Birmingham Women’s Hospital Milk Bank after the study 118 
protocol was approved by Warwickshire Research Ethics Committee and the R&D 119 
Department in Birmingham Women’s NHS foundation trust. Informed consent was obtained 120 
from all the participants before sample collection. Samples collected in 2010 were kept in 121 
clean screw-capped glass containers and transferred from the Milk Bank to the laboratory in 122 
special ice boxes then stored at -20ºC until the time of analysis. Due to ethical regulations, 123 
the samples were collected in a completely anonymous fashion with all participant 124 
information kept strictly confidential. For the purpose of this study, only 1 milk sample was 125 
collected from each mother during her first 6 month of lactation.    126 
Sample extraction 127 
Accurately weighted aliquots of the freeze-dried samples (~ 2 g) were loaded into pre-128 
cleaneds 66 mL Accelerated Solvent Extraction (ASE 300, Dionex Inc., UK) cells containing 129 
1.5 g florisil, 3 g alumina, 5 g anhydrous Na2SO4 and hydromatrix (Varian Inc., UK) to fill 130 
the void volume of the cells, spiked with 25 ng of each of 13C-labelled BDE-47, BDE-99, 131 
BDE-153, BDE-183, BDE-209 as internal (surrogate) standards. The ASE cells were 132 
extracted with hexane:dichloromethane (1:9, v/v) at 90 ˚C and 1500 psi. The heating time was 133 
5 minutes, static time 4 min, purge time 90 s, flush volume 50%, with three static cycles. The 134 
lipid weight of the studied samples was determined gravimetrically on separate aliquots using 135 
a standard procedure (The European Standard EN 1528-2, 1996; see supplementary data for 136 
more details). 137 
 138 
Sample Clean-up 139 
The crude extracts were concentrated to 0.5 mL using a Zymark Turbovap® II (Hopkinton, 140 
MA, USA) then washed with 3 mL of 98% sulfuric acid. After phase separation, the hexane 141 
layer was transferred onto a florisil column topped with sodium sulfate and eluted with 25 142 
mL of hexane:dichloromethane (1:1, v/v). The eluate was evaporated to dryness under a 143 
gentle stream of N2 and the dried extract reconstituted in 200 µL of 13C-BDE-100 (25 pg µL-1 144 
in methanol) used as recovery determination (or syringe) standard to determine the recoveries 145 
of internal standards for QA/QC purposes. 146 
 147 
LC-APPI-MS/MS analysis 148 
Sample analysis was carried out using an LC-MS/MS system composed of a dual pump 149 
Shimadzu LC-20AB Prominence liquid chromatograph equipped with SIL-20A autosampler, 150 
a DGU-20A3 vacuum degasser coupled to a Sciex API 2000 triple quadrupole mass 151 
spectrometer. Details of the multi-residue analytical methodology used for separation and 152 
quantification of the studied PBDEs can be found elsewhere (Abdallah, et al. 2009). (A brief 153 
description is given in the supplementary data section). 154 
 155 
Comparison of PBDE intake to human body burdens. 156 
We have previously estimated UK adult intake of the target PBDEs via inhalation, dust 157 
ingestion and diet (Harrad and Abdallah 2011; Harrad, et al. 2006; Harrad, et al. 2008a; 158 
Harrad, et al. 2008b) (A summary of the assumptions on which these estimations are based is 159 
provided as supplementary data). To examine the relationship between these estimated 160 
intakes and the body burdens indicated via human milk samples, a simple one-compartment, 161 
first order pharmacokinetic (PK) model was used. The studied PBDEs were hypothesized to 162 
accumulate in lipids (the single compartment in the model). Therefore, the change in PBDE 163 
















Where CPBDE is the compound specific concentration in lipids (ng g-1 lw); IPBDE is the daily 166 
intake of the target BFR (ng day-1); AFPBDE is the absorption fraction (unitless); BL is body 167 
lipid mass (g) and KPBDE is the compound specific first order dissipation rate (day-1).  168 
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Where CPBDE (0) is the studied PBDE body lipid concentration at time 0 (initial concentration 171 
before intake).  172 
Assuming a constant dose over time at constant body lipid mass, the steady state PBDE lipid 173 
concentration can be calculated from equation 3. It is stressed that the assumption of steady 174 





AFxIC =  176 
Quality assurance/Quality control 177 
Good recoveries (68-106%) of the 13C-labelled internal standards were obtained for all the 178 
studied compounds (table SI-4). Further evaluation of the method extraction/clean up 179 
performance was achieved via spiking milk samples (n=6) with 13C-BDE-154 prior to freeze 180 
drying and excellent recoveries (>90%) were obtained (table SI-5).  181 
No target compounds were detected in method blanks (n=5; consisting of 2 g pre-extracted 182 
anhydrous sodium sulfate treated exactly as a sample) or field blanks (n=5; consisting of ~2 g 183 
of broken pieces of the glass milk containers treated exactly as a sample). Therefore, there 184 
was no need for blank correction of concentrations and method limits of detection (LOD) and 185 
quantification (LOQ) were estimated based on 3:1 and 10:1 S:N ratios respectively.  186 
The accuracy and precision of the analytical method applied for PBDE determination was 187 
assessed via replicate analysis (n=10) of NIST SRM 2585. The results obtained compared 188 
favourably with the reported reference values (table SI-6a).  189 
Results and discussion 190 
Concentrations of Σtri-hexa BDEs in UK human milk 191 
While none of the investigated hepta- to nona-BDE congeners were above LOQ, BDE-47 192 
was quantified in all the analysed samples contributing 34-74% to Σtri-hexa BDEs (Table 1). 193 
The predominant BDE congeners in the studied human milk were in the order BDE-47 > 194 
BDE-153> BDE-99. These 3 congeners constituted an average of 85% of the quantified Σtri-195 
hexa BDEs in the studied samples. This is in agreement with previous reports of PBDEs in 196 
human milk from various countries (Frederiksen, et al. 2009). Interestingly, a higher average 197 
level of BDE-153 (1100 pg g-1 lw) than that of BDE-99 (710 pg g-1 lw) was observed (Table 198 
1). While this differs from the relative contribution of these 2 PBDE congeners in the 199 
commercial PentaBDE formulations (La Guardia, et al. 2006), several authors have reported 200 
higher levels of BDE-153 than BDE-99 in human milk (Ben Hassine, et al. 2012; Dunn, et al. 201 
2010; Frederiksen, et al. 2009). In addition, a recent study has reported BDE-153 as the 202 
dominant congener in 5 human breast milk samples from California (Park, et al. 2011). 203 
Furthermore, a study of PBDEs in human milk from the Faroe islands also reported 204 
predominance of BDE-153 (Fangstrom, et al. 2005). However, such high levels of BDE-153 205 
could not be associated with high consumption of seafood diet in the studied population, 206 
indicating that dietary exposure was not the reason for the elevated BDE-153 concentrations 207 
in breast milk. Therefore, we hypothesize that the relatively higher contribution of BDE-153 208 
to Σtri-hexa BDEs in human milk samples than expected from the PentaBDE technical 209 
mixture may be attributed to 2 main factors:  210 
First, the high bioaccumulation potential of BDE-153 in lipids (as evidenced by a half-life of 211 
6.5 years compared to 1.8 and 2.9 years for BDE-47 and BDE-99 respectively (Geyer, et al. 212 
2004)) which indicates that over time, BDE-153 will become the predominant congener in 213 
the body. 214 
Second, the possible production of BDE-153 as a result of BDE-209 metabolic stepwise 215 
meta-meta debromination (Roberts, et al. 2011). This stepwise debromination was previously 216 
observed in peregrine falcon eggs from California, where BDE-153 was the dominant 217 
congener only in eggs with high levels of BDE-209 (Holden, et al. 2009). Interestingly, while 218 
concentrations of BDE-153 in this study were significantly (r = 0.443; p<0.01) correlated 219 
with those of BDE-209, no other statistically significant (p<0.05) correlation was observed 220 
between BDE-209 levels and any of the PBDE congeners or Σtri-hexa BDEs in the analyzed 221 
samples. This further supports the hypothesis that metabolic degradation of BDE-209 yields 222 
the highly bioaccumulative BDE-153 resulting in elevated concentrations of the latter in 223 
human milk. 224 
 While the levels of Σtri-hexa BDEs in this study (Table 1) are slightly lower than those 225 
reported in UK human milk samples collected in 2003 (n=54, average = 6.3 ng g-1 lw), these 226 
concentrations are still at the high end of those reported from other European, Asian, African 227 
and Australasian countries (Table 2). On the other hand, Σtri-hexa BDEs in UK human milk 228 
are substantially lower than those reported from USA and Canada (Table 2) which is in 229 
agreement with the far more extensive production and use of the PentaBDE technical 230 
formulation in North America than elsewhere (BSEF 2013). 231 
 232 
Concentrations of BDE-209 in UK human milk 233 
BDE-209 was above LOQ in 69% of the studied milk samples ranging from <0.06-0.92 ng g-234 
1 lw (Table 1). To the authors’ knowledge, this paper is the first to report concentrations of 235 
BDE-209 in UK human milk. Interestingly, these levels are at the lower end of BDE-209 236 
concentrations reported in human milk from other European countries (Table 2) despite the 237 
substantially higher levels of this BFR reported in UK indoor dust compared to the rest of 238 
Europe (Harrad, et al. 2010) and the reported higher usage of BDE 209 in the UK than other 239 
EU countries (EU Risk Assessment Report 2002). This may indicate that while indoor dust 240 
ingestion is the major pathway of external human exposure to BDE-209 (Harrad, et al. 2008a; 241 
Lorber 2008), the high levels of this compound in indoor dust do not significantly contribute 242 
to human body burdens. Our research group have recently reported on the very low 243 
bioaccessibility (~14%) of BDE-209 in indoor dust across the human gastrointestinal tract 244 
(GIT) following oral ingestion (Abdallah, et al. 2012), consistent with animal studies 245 
reporting low bioavailability (4-26%) of BDE-209 (Huwe and Smith 2007; Sandholm, et al. 246 
2003). Such poor uptake of BDE-209 from the GIT, combined with its very short human 247 
half-life (t0.5 = 7 days, (Geyer, et al. 2004) and its preferential partitioning to serum rather 248 
than milk fat (Mannetje, et al. 2012) may result in the apparently low influence of BDE-209 249 
concentrations in indoor dust on UK adult body burdens. 250 
 251 
Nursing infants’ dietary intake of PBDEs via breast milk: 252 
Breast milk is a recognized medium for direct transfer of POPs to nursing infants. To 253 
estimate the nursing infants’ dietary intake of the studied BFRs via breast milk, equation 4 254 






=  256 
Where Di is the estimated dietary intake (ng kg-1 bw day-1); CPBDE is the concentration of 257 
target PBDE in milk (ng g-1 lw); Flipid is the daily lipid intake via breast milk (g day-1) and Bw 258 
is the body weight (4.14 kg) (U.S. EPA 2002.). The infant’s daily lipid intake via breast milk 259 
(Flipid) was calculated based using U.S. EPA guidelines (U.S. EPA 2002.) which suggest an 260 
average intake of 702 mL milk per day for a 1 month old infant weighing 4.14 kg. The 261 
median lipid content of the analyzed milk samples was 3.47 g lipid per 100 mL of breast milk 262 
resulting in a daily lipid intake of 24.4 g lipid day-1. 263 
Table 3 shows the estimated dietary intake of target PBDEs via breast milk using different 264 
exposure scenarios (in which exposure factors (e.g. dust ingestion rate) were held constant 265 
but using different PBDE concentrations (e.g. 25th percentile) derived from our breast milk 266 
data). While the estimated average UK infant exposure to Σtri-hexa BDEs is much lower than 267 
that in North America (Park, et al. 2011), a 1 month-old infant in the UK is still more 268 
exposed to Σtri-hexa BDEs than in several other European countries via breast milk 269 
(Roosens, et al. 2010). Interestingly, the average exposure of a nursing infant to Σtri-hexa 270 
BDEs via breast milk exceeded upper-bound dietary intakes of UK adults and toddlers (UK 271 
Food Standards Agency 2006) (Figure 1), while for BDE-209, dietary exposure was the most 272 
significant exposure pathway for toddlers.  273 
The low concentrations of BDE-209 in the studied milk samples resulted in much lower 274 
exposure of UK nursing infants to this contaminant than the USEPA reference daily dose 275 
(RfD) of 7 µg kg bw-1 day-1.  Similarly, our estimated UK infant daily intakes (Table 3) are 276 
lower than the USEPA reference doses for BDE-47 (100 ng kg bw-1 day-1 for 277 
neurodevelopmental toxicity) and Σtri-hexa BDEs (2000 ng kg bw-1 day-1 for liver toxicity) 278 
(U.S.EPA 2008). However, the median level of Σtri-hexa BDEs in this study (4.98 ng kg-1 279 
lw) is slightly higher than that associated with congenital cryptorchidism (4.16 ng kg-1 lw; 280 
p<0.01) in Danish-Finnish newborn boys (Crump, et al. 2010) and generally in line with 281 
levels associated with irregular menstruation periods in a Taiwanese population (Chao, et al. 282 
2010). While this does not provide solid evidence on the potential health effects associated 283 
with the reported levels of PBDEs in human milk due to the lack of relevant studies in the 284 
UK, our results certainly raise concerns about potential adverse effects resulting from 285 
exposure of infants and mothers to PBDEs. Although breastfeeding mothers should be 286 
encouraged and supported due to the well-documented beneficial effects of breast feeding, 287 
scientific studies ought to characterize and measure the contaminants in breast milk so that 288 
protective measures may be provided, if necessary, to avoid any potential harmful effects on 289 
the mother or the newborn. 290 
 291 
Comparison of PBDEs intake to human body burdens 292 
To convert daily adult intakes of BFRs via different exposure pathways to expected body 293 
burdens, the bioaccessible fractions of each target compound  (Abdallah, et al. 2012) were 294 
used in equation 3 to substitute for AFPBDE in case of exposure via dust ingestion or diet, 295 
while the inhalable fraction was assumed to be 100% bioavailable. The body lipid mass was 296 
estimated based on a 25% body fat for an average adult weighing 70 kg (U.S. EPA 1997). 297 
Finally, KPBDE was calculated as 0.693/t0.5; where t0.5 is the half-life of the studied BFR in the 298 
body lipid compartment (Geyer, et al. 2004).  299 
In general, good agreement was observed between the predicted and the observed body 300 
burdens of main target PBDEs (table 4) given the simplicity of the model used (e.g. only one 301 
body compartment was studied), the dearth of information regarding the half-lives of 302 
different PBDE congeners in various compartments of the human body, and the uncertainty 303 
about the bioavailability of the studied compounds from different exposure routes.  304 
In addition, the PK model used here does not estimate human exposure via routes such as 305 
dermal contact and water intake. This is due to the high uncertainty and complete absence of 306 
experimental data on the extent of BFR absorption via dermal contact by humans coupled 307 
with the expected minimal contribution of water intake to the overall daily exposure to BFRs 308 
based on the very low aqueous solubility of PBDEs.  309 
Nevertheless, the good agreement between the predicted and observed results indicates that 310 
the studied exposure routes are the main pathways driving UK adult body burdens of PBDEs. 311 
This is in line with the findings of Lorber (Lorber 2008) who studied the exposure of 312 
Americans to PBDEs and reported indoor dust ingestion as the main route of exposure 313 
followed by diet and inhalation. However, more research is required for assessment of the 314 
bioavailability of various PBDEs via different exposure routes and determination of t0.5 of 315 
PBDEs in various human tissues. 316 
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Table1: Statistical summary of PBDE concentrations (ng g-1 lw) in human milk samples 540 



















Average 3.30 <0.05 0.08 0.71 0.45 1.10 0.30 5.95 0.31 
SD* 3.25 0.08 0.15 0.67 0.39 1.05 0.30 5.35 0.30 
Median 2.80 <0.05 <0.05 0.69 0.38 0.91 0.21 5.00 0.25 
DF** (%) 100 20 46 94 89 97 77 100 69 
LOQ 0.043 0.045 0.051 0.055 0.053 0.058 0.059 N/A# 0.062 
Minimum 0.17 <0.05 <0.05 <0.06 <0.05 <0.06 <0.06 0.2 <0.06 
25th %ile 0.78 <0.05 <0.05 0.20 0.12 0.35 0.07 1.70 <0.06 
75th  %ile 5.15 <0.05 0.09 0.85 0.70 1.43 0.55 9.55 0.58 
Maximum 14.65 0.45 0.83 3.43 1.86 4.57 11.10 26.10 0.92 
* Standard deviation. 542 
** Detection frequency. 543 








Table 2: Average concentrations of PBDEs (ng g-1 lw) in human milk samples from 552 
different countries. 553 





UK  2009-10 35 5.9 0.3 (this study) 
UK 2001-03 54 6.3 N/A* (Kalantzi, et al. 2004) 
Norway 2003-09 393 2.7 0.6 (Thomsen, et al. 2010) 
Sweden 1996-2006 276 3.4 N/A (Lignell, et al. 2011) 
France 2004-06 93 2.5 1.6 (Antignac, et al. 2009) 
Spain 2005 9 2.1 2.5 (Gomara, et al. 2011) 
Belgium 2006 22 3.0 5.9 (Roosens, et al. 2010) 
Italy 2005-07 13 1.3 N/A (Alivernini, et al. 2011) 
USA 2002 47 34.0 0.9 (Schecter, et al. 2003) 
Canada 2003 10 50.4 0.4 (She, et al. 2007) 
Australia 2007 10 7.6 0.3 (Toms, et al. 2009) 
China 2004 19 2.5 3.0 (Sudaryanto, et al. 2008) 
India 2009 45 1.1 0.4 (Devanathan, et al. 2012) 
Korea 2008-09 21 2.7 N/A (Kim, et al. 2011) 
Tunisia 2010 36 8.3 N/A (Ben Hassine, et al. 2012) 








Table 3: Estimated exposure* (ng (kg bw)-1 day-1) of a 1 month old infant to the target 562 
BFRs via breast milk under different scenarios**. 563 
 
25th %ile Average Median 75th %ile 
BDE-47 4.6 19.3 16.3 30.3 
BDE-99 1.2 4.2 4.0 5.1 
BDE-100 0.7 2.7 2.2 4.2 
BDE-153 2.1 6.5 5.3 8.4 
BDE-154 0.4 1.7 1.3 3.2 
Σtri-hexa BDEs 10.0 34.9 29.4 56.4 
BDE-209 <0.1 1.8 1.2 3.4 
 564 
* Values below LOQ were assumed to be 1/2 LOQ. 565 
** Based on an average body weight of 4.14 kg and a daily lipid intake of 24.4 g lipid day-1 566 








Table 4: Comparison of predicted adult body burdens arising from average and median 575 
daily exposures# to major target PBDEs with observed levels in human milk samples. 576 
 BDE-47 BDE-99 BDE-100 BDE-153 BDE-154 Σ5BDEs BDE-209 
Average intake* (ng day-1) 
Dusta 1.10 1.80 0.24 0.31 0.17 3.70 4270 
Dietb 35 30 5.60 7.00 2.80 80 310 
Airc 0.90 0.60 0.14 0.05 0.03 1.70 9.40 
Median intake* (ng day-1) 
Dusta 0.29 0.67 0.08 0.12 0.01 1.20 2975 
Dietb 35 30 5.60 7.00 2.80 80 310 
Airc 0.20 0.30 0.04 0.01 0.01 0.55 7.40 
Average predicted body burdens (ng g-1 lw) 
Dust 0.06 0.05 0.01 0.02 0.01 0.14 0.34 
Diet 3.33 1.39 0.38 1.15 0.16 6.40 0.03 
Air 0.11 0.05 0.01 0.01 0.01 0.20 0.01 
Sum 3.49 1.49 0.40 1.19 0.18 6.74 0.38 
Median predicted body burdens (ng g-1 lw) 
Dust 0.01 0.02 0.00 0.01 0.00 0.04 0.24 
Diet 3.33 1.44 0.38 1.15 0.16 6.45 0.03 
Air 0.03 0.03 0.00 0.00 0.00 0.06 0.00 
Sum 3.36 1.48 0.39 1.16 0.16 6.55 0.27 
Observed body burdens (ng g-1 lw) 
Average 3.28 0.71 0.45 1.09 0.28 5.92 0.31 
Median 2.77 0.68 0.38 0.9 0.21 4.98 0.24 
 577 
# Values below LOQ were assumed to be 1/2 LOQ. 578 
* Based on average adult dust ingestion rate of 20 mg day-1 (Jones-Otazo, et al. 2005), 579 
average inhalation rate of  20 m3 day-1 (Currado and Harrad 1998) and average adult weight 580 
of 70 kg.  581 
a Estimated from reference (Harrad, et al. 2008a); b Estimated from reference (UK Food 582 
Standards Agency 2006); c Estimated from references (Harrad, et al. 2006; Stapleton, et al. 583 





Figure 1: Average estimates of dietary exposure (ng (kg bw)-1 day-1) of UK adults*, 589 
toddlers* and breast-fed infants** to PBDEs.  590 
 591 
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